CD44 and neoplasm: Moreover, we observed SC144@HABN treatment lost its anti-tumor efficacy in mice bearing CD44-KO MC38 tumor cells pre-treated in vitro with CRISPR/Cas9 to knock-down the CD44 expression (Fig. 3m, n, Supplementary Fig. 20).